436 related articles for article (PubMed ID: 9688985)
21. Renoprotective effects of a combined endothelin type A/type B receptor antagonist in experimental malignant hypertension.
Kohno M; Yokokawa K; Yasunari K; Kano H; Minami M; Ueda M; Tatsumi Y; Yoshikawa J
Metabolism; 1997 Sep; 46(9):1032-8. PubMed ID: 9284892
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of soluble guanylyl cyclase in the inner medulla of DOCA-salt hypertensive rats.
Taylor TA; Pollock JS; Pollock DM
Vascul Pharmacol; 2003 Oct; 40(3):155-60. PubMed ID: 13678647
[TBL] [Abstract][Full Text] [Related]
23. Apoptosis in aorta of deoxycorticosterone acetate-salt hypertensive rats: effect of endothelin receptor antagonism.
Sharifi AM; Schiffrin EL
J Hypertens; 1997 Dec; 15(12 Pt 1):1441-8. PubMed ID: 9431850
[TBL] [Abstract][Full Text] [Related]
24. Local administration of ETA (but not ETB) blockers into the PAG area of the brain decreases blood pressure of DOCA-salt rats.
Di Filippo C; D'Amico M; Piegari E; Rinaldi B; Filippelli A; Rossi F
Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):123-6. PubMed ID: 12122498
[TBL] [Abstract][Full Text] [Related]
25. Endothelin-1 expression in blood vessels of DOCA-salt hypertensive rats treated with the combined ETA/ETB endothelin receptor antagonist bosentan.
Larivière R; Sventek P; Thibault G; Schiffrin EL
Can J Physiol Pharmacol; 1995 Mar; 73(3):390-8. PubMed ID: 7544236
[TBL] [Abstract][Full Text] [Related]
26. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension.
Oyekan AO; McAward K; Conetta J; Rosenfeld L; McGiff JC
Am J Physiol; 1999 Mar; 276(3):R766-75. PubMed ID: 10070137
[TBL] [Abstract][Full Text] [Related]
27. Role of endothelin-1 and the ETA receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension.
Fujita K; Matsumura Y; Kita S; Miyazaki Y; Hisaki K; Takaoka M; Morimoto S
Br J Pharmacol; 1995 Mar; 114(5):925-30. PubMed ID: 7780646
[TBL] [Abstract][Full Text] [Related]
28. Effects of the endothelin ETA-receptor antagonist FR139317 on development of hypertension and cardiovascular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats.
Fujita K; Matsumura Y; Miyazaki Y; Takaoka M; Morimoto S
Jpn J Pharmacol; 1996 Apr; 70(4):313-9. PubMed ID: 8774759
[TBL] [Abstract][Full Text] [Related]
29. Cardiac microvasculature in DOCA-salt hypertensive rats : effect of endothelin ET(A) receptor antagonism.
Larouche I; Schiffrin EL
Hypertension; 1999 Oct; 34(4 Pt 2):795-801. PubMed ID: 10523363
[TBL] [Abstract][Full Text] [Related]
30. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension.
Rahmouni K; Sibug RM; De Kloet ER; Barthelmebs M; Grima M; Imbs JL; De Jong W
Eur J Pharmacol; 2002 Feb; 436(3):207-16. PubMed ID: 11858800
[TBL] [Abstract][Full Text] [Related]
31. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats.
Schiffrin EL; Sventek P; Li JS; Turgeon A; Reudelhuber T
Br J Pharmacol; 1995 Aug; 115(8):1377-81. PubMed ID: 8564194
[TBL] [Abstract][Full Text] [Related]
32. Reduced NO production rapidly aggravates renal function through the NF-κB/ET-1/ETA receptor pathway in DOCA-salt-induced hypertensive rats.
Kimura K; Ohkita M; Koyama M; Matsumura Y
Life Sci; 2012 Oct; 91(13-14):644-50. PubMed ID: 22569294
[TBL] [Abstract][Full Text] [Related]
33. Role of the renal nerves in the maintenance of DOCA-salt hypertension in the rat. Influence on the renal vasculature and sodium excretion.
Katholi RE; Naftilan AJ; Bishop SP; Oparil S
Hypertension; 1983; 5(4):427-35. PubMed ID: 6345357
[TBL] [Abstract][Full Text] [Related]
34. Exaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension.
Matsumura Y; Kuro T; Kobayashi Y; Konishi F; Takaoka M; Wessale JL; Opgenorth TJ; Gariepy CE; Yanagisawa M
Circulation; 2000 Nov; 102(22):2765-73. PubMed ID: 11094045
[TBL] [Abstract][Full Text] [Related]
35. ETA receptor mediates altered leukocyte-endothelial cell interaction and adhesion molecules expression in DOCA-salt rats.
Callera GE; Montezano AC; Touyz RM; Zorn TM; Carvalho MH; Fortes ZB; Nigro D; Schiffrin EL; Tostes RC
Hypertension; 2004 Apr; 43(4):872-9. PubMed ID: 14993193
[TBL] [Abstract][Full Text] [Related]
36. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension.
Callera GE; Touyz RM; Teixeira SA; Muscara MN; Carvalho MH; Fortes ZB; Nigro D; Schiffrin EL; Tostes RC
Hypertension; 2003 Oct; 42(4):811-7. PubMed ID: 12913063
[TBL] [Abstract][Full Text] [Related]
37. Natriuretic peptide gene expression in DOCA-salt hypertension after blockade of type B endothelin receptor.
Bianciotti LG; de Bold AJ
Am J Physiol Heart Circ Physiol; 2002 Mar; 282(3):H1127-34. PubMed ID: 11834512
[TBL] [Abstract][Full Text] [Related]
38. Effects of alpha-lipoic acid on deoxycorticosterone acetate-salt-induced hypertension in rats.
Takaoka M; Kobayashi Y; Yuba M; Ohkita M; Matsumura Y
Eur J Pharmacol; 2001 Jul; 424(2):121-9. PubMed ID: 11476758
[TBL] [Abstract][Full Text] [Related]
39. Effect of vasopressin antagonism on structure and mechanics of small arteries and vascular expression of endothelin-1 in deoxycorticosterone acetate salt hypertensive rats.
Intengan HD; He G; Schiffrin EL
Hypertension; 1998 Oct; 32(4):770-7. PubMed ID: 9774378
[TBL] [Abstract][Full Text] [Related]
40. NADPH oxidase-derived superoxide augments endothelin-1-induced venoconstriction in mineralocorticoid hypertension.
Li L; Watts SW; Banes AK; Galligan JJ; Fink GD; Chen AF
Hypertension; 2003 Sep; 42(3):316-21. PubMed ID: 12885792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
